CAR T Therapy May Cause Rare Cancer & How CRISPR Could Be The Solution

CAR T therapy safety falls into question as the FDA investigates reports of rare T cell lymphoma after treatment. This concern could be resolved with CRISPR technology.
Source: Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news